Ignite Creation Date:
2024-05-05 @ 4:54 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00338481
Status:
COMPLETED
Last Update Posted:
2011-07-27
First Post:
2006-06-16
Brief Title:
Red Morphine Drops for Symptomatic Treatment of Dyspnoea in Lung Cancer
Sponsor:
Sankt Lukas Hospice
Organization:
Sankt Lukas Hospice
Study Overview
Official Title:
Red Morphine Drops for Symptomatic Treatment of Dyspnoea in Terminal Patients With Primary Lung Cancer or Lung metastases-a Pilot Study
Status:
COMPLETED
Status Verified Date:
2011-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to test whether red morphine drops applied in the mouth are superior to an equivalent amount of morphine applied as subcutaneous injection for the relief of breathlessness in terminal patients suffering from primary lung cancer or lung metastases
Detailed Description:
Breathlessness or dyspnea in terminal cancer patients with lung cancer is common and opioids such as morphine is the mainstay of symptomatic treatment Subcutaneous administration of morphine provides fast symptomatic relief but it has been the impression in our institution that red morphine drops applied orally may have equal or better efficacy and faster onset time
Comparison Patients with lung cancer or lung metastases with moderate to severe dyspnea at rest are treated with either orally applied red morphine drops or an equivalent amount of morphine applied subcutaneously
Comparison Patients with lung cancer or lung metastases with moderate to severe dyspnea at rest are treated with either orally applied red morphine drops or an equivalent amount of morphine applied subcutaneously
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None